Sonali Deo, MD
Family Medicine · Oliver Springs, TNNPI 1215121611
Payments from drug & device makers
Across 106 payments — averaging $20.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$368
- AbbVie$357
- GSK$351
- Pfizer$219
- Boehringer Ingelheim$180
- Amgen$117
- plus $544 from 16 others
What the payments were for
- Food & beverage$2,07597%
- Education$623%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 13 | $368 |
| AbbVie | 24 | $357 |
| GSK | 23 | $351 |
| Pfizer | 9 | $219 |
| Boehringer Ingelheim | 4 | $180 |
| Amgen | 7 | $117 |
| Abiomed | 1 | $110 |
| Xeris Pharmaceuticals, Inc. | 3 | $63 |
| Sumitomo Pharma America, Inc. | 3 | $48 |
| Lilly USA, LLC | 3 | $41 |
| Otsuka America Pharmaceutical, Inc. | 2 | $41 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $37 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Kyowa Kirin, Inc. | 2 | $30 |
| Astellas Pharma US Inc | 2 | $28 |
| Merck | 1 | $18 |
| Nevro Corp. | 1 | $18 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Exact Sciences | 1 | $17 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Abbott | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,137 in reported general payments places this provider in the 70th percentile of 2,087 family medicine providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 148 | $119,990 |
| OzempicSemaglutide | 91 | $110,273 |
| MounjaroTirzepatide | 69 | $79,536 |
| TrulicityDulaglutide | 65 | $78,546 |
| RybelsusSemaglutide | 35 | $55,156 |
| JardianceEmpagliflozin | 56 | $54,196 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 45 | $35,707 |
| LinzessLinaclotide | 43 | $35,321 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 115 | $25,967 |
| XareltoRivaroxaban | 18 | $22,393 |
| FarxigaDapagliflozin Propanediol | 15 | $20,850 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 49 | $16,050 |
| VascepaIcosapent Ethyl | 21 | $15,498 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 26 | $10,212 |
| JanuviaSitagliptin Phosphate | 12 | $10,088 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $368 | $165,428126 claims |
| Lilly USA, LLCMounjaro, Trulicity | $41 | $158,082134 claims |
| PfizerEliquis, Abrysvo | $219 | $136,039197 claims |
| GSKTrelegy Ellipta, Shingrix | $351 | $61,675160 claims |
| Boehringer IngelheimJardiance | $180 | $54,19656 claims |
| AbbVieLinzess, Ubrelvy | $357 | $41,70254 claims |
| MerckJanuvia | $18 | $10,08812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 2,087 family medicine providers in Tennessee.
Other family medicine in Oliver Springs
- Rickey ManningKnoxville$8.1M
- Kymberly MoyerGallatin$5.9M
- Natasha BallardChattanooga$5.7M
- Hina BudhwaniNashville$4.7M
- Paul WakefieldKnoxville$4.3M
- Emily HubbsKingsport$2.8M
- Jerry PunchKnoxville$2.1M
- Bridgette FraneyNashville$2M
- Andrew BrockmyreBristol$1.8M
- Marcus LeeTullahoma$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.